Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass

We sought to evaluate the efficacy of recombinant human antithrombin III for restoration of heparin responsiveness in heparin-resistant patients scheduled for cardiac surgery. This was a multicenter, randomized, double-blind, placebo-controlled study in heparin-resistant patients undergoing elective...

Ausführliche Beschreibung